What the Poppins Clinical decision reveals about evidence, patient value, health-system capacity and the economics of early digital reimbursement. A precedent with wider significance France has granted early PECAN reimbursement …
Tag:
#AIReimbursement
-
-
What a Dutch population study of MammaPrint and Oncotype DX reveals about access, adoption and chemotherapy decisions A short evidence blog from Odelle Technology 9% → 25% → 37% Use …
-
Early Value Assessments are not shortcuts to reimbursement. They are tests of whether a technology deserves the NHS’s attention while uncertainty is still unresolved. In recent years, NICE has been …
-
How the New Coding and Payment Model Is Reshaping Hospital Care and Which Technologies Fit It Best For 2026, the German Hybrid-DRG system underwent a significant expansion, increasing to 69 …
-
Germany rarely announces a reimbursement change with fanfare. It tends to arrive indirectly through regulation, measurement, and administrative architecture. Sepsis is the latest example. From 1 January 2026, sepsis care …
-
The HAS / CNEDiMTS route explained science, law, and real-world decisions France operates one of the most structured and evidence-based reimbursement systems for medical devices in Europe. Access is not …
-
MedTech / IVD VC Funding: the investor is modelling reimbursement physics, not admiring your science Most founders pitch MedTech as if capital is attracted by novelty. In regulated healthcare, the …
-
How to Use German NUB Reimbursement Without Getting Trapped After nearly two decades of operational data, one conclusion is unavoidable: German NUB reimbursement is not a neutral innovation gateway. It …